Published in J Neurosci on February 18, 2009
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
The analgesic potential of cannabinoids. J Opioid Manag (2010) 1.16
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther (2009) 1.12
Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A (2013) 1.00
Cannabinoids and Epilepsy. Neurotherapeutics (2015) 0.91
Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol (2012) 0.88
Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120. J Leukoc Biol (2012) 0.85
Contribution of electromechanical coupling between Kv and Ca v1.2 channels to coronary dysfunction in obesity. Basic Res Cardiol (2013) 0.84
The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol (2014) 0.84
Cellular calcium dynamics in lactation and breast cancer: from physiology to pathology. Am J Physiol Cell Physiol (2013) 0.84
Molecular identity and functional properties of the mitochondrial Na+/Ca2+ exchanger. J Biol Chem (2012) 0.84
Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis (2013) 0.82
Caged mitochondrial uncouplers that are released in response to hydrogen peroxide. Tetrahedron (2010) 0.82
Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol (2014) 0.82
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol (2010) 0.80
Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol (2014) 0.80
Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics (2015) 0.79
Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol (2013) 0.79
The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J Neuroimmune Pharmacol (2015) 0.79
Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism. Br J Pharmacol (2012) 0.78
Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage. Front Cell Neurosci (2016) 0.78
Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br J Pharmacol (2011) 0.77
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology (Berl) (2012) 0.76
Cannabis microbiome sequencing reveals several mycotoxic fungi native to dispensary grade Cannabis flowers. F1000Res (2015) 0.76
Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology (Berl) (2010) 0.76
Novel features on the regulation by mitochondria of calcium and secretion transients in chromaffin cells challenged with acetylcholine at 37°C. Physiol Rep (2013) 0.76
Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. Front Pharmacol (2017) 0.75
The quantal catecholamine release from mouse chromaffin cells challenged with repeated acetylcholine pulses is regulated by the mitochondrial Na(+) /Ca(2+) exchanger. J Physiol (2016) 0.75
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget (2016) 0.75
Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol (2016) 0.75
Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability. ACS Med Chem Lett (2016) 0.75
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals (Basel) (2010) 0.75
Glutamate receptor function in learning and memory. Behav Brain Res (2003) 2.72
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol (2005) 1.60
Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res (2008) 1.60
In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Exp Neurol (2011) 1.45
Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol (2002) 1.31
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol (2007) 1.15
Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther (2002) 1.13
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
The cholinergic system and hippocampal plasticity. Behav Brain Res (2010) 1.11
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol (2004) 1.10
Involvement of the cholinergic system in conditioning and perceptual memory. Behav Brain Res (2011) 1.10
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol (2004) 1.09
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol (2009) 1.08
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res (2011) 1.03
The cholinergic system and spatial learning. Behav Brain Res (2010) 1.03
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma (2006) 1.03
Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol (2010) 1.03
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology (2004) 1.01
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem (2003) 1.01
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J Alzheimers Dis (2011) 1.01
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2011) 1.00
EEG, activity, and sleep architecture in a transgenic AβPPswe/PSEN1A246E Alzheimer's disease mouse. J Alzheimers Dis (2010) 1.00
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol (2010) 0.98
Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology (2005) 0.98
Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimers Dis (2007) 0.97
Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem (2005) 0.96
A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Int J Dev Neurosci (2013) 0.96
Inference of Granger causal time-dependent influences in noisy multivariate time series. J Neurosci Methods (2011) 0.93
Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. Psychopharmacology (Berl) (2007) 0.92
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol (2007) 0.92
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci (2012) 0.90
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun (2005) 0.88
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol (2012) 0.88
AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol (2012) 0.87
The seed extract of Cassia obtusifolia offers neuroprotection to mouse hippocampal cultures. J Pharmacol Sci (2008) 0.87
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol (2014) 0.86
Modulation of hippocampal calcium signalling and plasticity by serine/threonine protein phosphatases. J Neurochem (2007) 0.84
Presynaptic group I metabotropic glutamate receptors modulate synaptic transmission in the rat superior colliculus via 4-AP sensitive K(+) channels. Br J Pharmacol (2003) 0.84
Enhanced hippocampal long-term potentiation in rats after chronic exposure to homocysteine. Neurosci Lett (2005) 0.82
WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behav Brain Res (2010) 0.82
Mapping changes in mouse brain metabolism with PET/CT. J Nucl Med (2013) 0.82
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem (2009) 0.82
A comparative study of the actions of alkylpyridinium salts from a marine sponge and related synthetic compounds in rat cultured hippocampal neurones. BMC Pharmacol (2007) 0.82
Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. Behav Brain Res (2006) 0.82
Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol (2013) 0.82
Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci (2007) 0.82
Differential toxicity of novel aluminium compounds in hippocampal culture. Neurotoxicology (2007) 0.82
Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neurosci Lett (2006) 0.81
Store-operated Ca2+ entry in hippocampal neurons: Regulation by protein tyrosine phosphatase PTP1B. Cell Calcium (2012) 0.81
Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem (2003) 0.80
Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. Psychopharmacology (Berl) (2002) 0.80
Sleep and hippocampus: do we search for the right things? Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.80
Long-term study of chronic oral aluminum exposure and spatial working memory in rats. Behav Neurosci (2002) 0.80
Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res (2012) 0.80
The bioassay of cannabinoids using the mouse isolated vas deferens. Methods Mol Med (2006) 0.79
A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats. Sleep Disord (2012) 0.78
No spatial working memory deficit in beta-amyloid-exposed rats. A longitudinal study. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.78
Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors. J Pharmacol Exp Ther (2005) 0.78
Age-dependent changes in hippocampal synaptic transmission and plasticity in the PLB1Triple Alzheimer mouse. Cell Mol Life Sci (2013) 0.77
Aluminum does not enhance beta-amyloid toxicity in rat hippocampal cultures. Brain Res (2010) 0.77
Culturing conditions determine neuronal and glial excitability. J Neurosci Methods (2010) 0.77
Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. ChemMedChem (2012) 0.77
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacol Res (2009) 0.77
Bi-directional alterations of LTP after acute homocysteine exposure. Behav Brain Res (2009) 0.76
Aluminium interferes with hippocampal calcium signaling in a species-specific manner. J Inorg Biochem (2010) 0.76
Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. Behav Pharmacol (2015) 0.76
Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. Eur J Med Chem (2012) 0.76
Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. Bioorg Med Chem Lett (2008) 0.76
Intracellular Ca2+ stores modulate SOCCs and NMDA receptors via tyrosine kinases in rat hippocampal neurons. Cell Calcium (2009) 0.76
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. Br J Pharmacol (2015) 0.76
Human erythroid cells are affected by aluminium. Alteration of membrane band 3 protein. Biochim Biophys Acta (2002) 0.75
Multivariate analysis of dynamical processes with applications to the neurosciences. Conf Proc IEEE Eng Med Biol Soc (2011) 0.75
18F-barbiturates are PET tracers with diagnostic potential in Alzheimer's disease. Chem Commun (Camb) (2013) 0.75
Alzheimer's disease pathology and the unfolded protein response: prospective pathways and therapeutic targets. Behav Pharmacol (2017) 0.75
Gamma-aminobutyric acid-induced calcium signalling in rat superior collicular neurones. Neurosci Lett (2002) 0.75
Sometimes you see them, sometimes you don't: IPSCs in the rat superficial superior colliculus. Exp Brain Res (2003) 0.75